Impact of co-morbidities in COVID -19 infected patients

Authors

  • Preeti Verma Government Medical College, Kannauj, Uttar Pradesh https://orcid.org/0000-0002-3951-4135
  • Sachin Chaudhary Government Medical College, Kannauj, Uttar Pradesh https://orcid.org/0000-0001-9932-9858
  • Samarjeet Kaur Ganesh Shankar Vidyarthi Memorial Medical College Medical school in Kanpur, Uttar Pradesh
  • Tanu Midha Government Medical College, Kannauj, Uttar Pradesh https://orcid.org/0000-0002-2631-672X
  • Dinesh Singh Martolia Government Medical College, Kannauj, Uttar Pradesh

DOI:

https://doi.org/10.47203/IJCH.2022.v34i01.006%20

Keywords:

COVID-19, SARS, MERS, COPD, RT –PCR

Abstract

Background- During the COVID- 19 pandemic in the first wave, infected patients age was range from 4 weeks to 90 years and those who have more age and with comorbidities are more susceptible to develop serious illness and have high mortality rates. Objective-To study the association between survivor vs non survivor on the basis of demographic profile and high risk factors. Material & methods: This study was done in the Government Medical College, Kannauj on the COVID-19 patients who were admitted in the isolation wards, from 1st September 2020 to December 31st 2020. Statistical Analysis- Analysis was done using SPSS- 23 trial version software. Results: case fatality rate was 2.7% in this study. Most common symptoms was cough (61.0%) and among these admitted patients the most common comorbidities was hypertension (26.7%), followed by diabetes (20.7%), and COPD (14.0%) respectively. Platelets (< 0.02), post prandial blood sugar (PPBS) (< 0.01) have significant role in survivability of COVID- 19 patients. Conclusion: This study concludes that those patients who were older in age and with comorbidity especially (hypertension, COPD, high PPBS, High platelets) have poorer prognosis as compare to those without.

Downloads

Download data is not yet available.

References

Chen N et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507–513.

https://doi.org/10.1016/s0140-6736(20)30211-7

Wei-jie Guan et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. : May 2020; 1455(5): 2000547.

Adekunle Sanyaolu, et al .Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med: jun 25, 2020: 1–8.

Ravi Dosi, Gaurav Jain and Abhishek Mehta. Clinical Characteristics, Comorbidities, and Outcome among 365 Patients of Coronavirus Disease 2019 at a Tertiary Care Centre in Central India.JAIP : September 2020;68.

Osibogun A et al. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PLoS ONE 16(3): e0248281. https://doi.org/10.1371/journal.pone.0248281

Safiya Richardson et al . Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. April 22, 2020; 323(20):2052-2059.

https://doi.org/10.3410/f.737797860.793574198

Divya Goel and Sudhir Kumar. Co-morbid conditions in COVID-19 patients in Uttarakhand state of India. http://www.jogh.org/documents/2021/jogh-11-03029.htm

https://doi.org/10.7189/jogh.11.03029

Downloads

Published

2022-03-31

How to Cite

1.
Verma P, Chaudhary S, Kaur S, Midha T, Martolia DS. Impact of co-morbidities in COVID -19 infected patients. Indian J Community Health [Internet]. 2022 Mar. 31 [cited 2022 May 25];34(1):26-9. Available from: https://iapsmupuk.org/journal/index.php/IJCH/article/view/2291

Issue

Section

Original Article

Most read articles by the same author(s)